期刊
ACTA BIOMATERIALIA
卷 157, 期 -, 页码 367-380出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.actbio.2022.12.007
关键词
Rheumatoid arthritis; Methotrexate; Nanomedicine; Macrophage; Lymphatic function
In this study, a inflammation-specific environment activated methotrexate-encapsulated nanomedicine (MTX@NPs) was developed for the treatment of rheumatoid arthritis (RA). It effectively accumulated in inflamed joints and released methotrexate in the specific RA microenvironment. MTX@NPs demonstrated a high therapeutic efficacy for RA with minimal systemic toxicity by suppressing inflammation response and improving lymphatic functions.
Rheumatoid arthritis (RA), as an autoimmune inflammatory disease, is featured by enhanced vascular permeability, irreversible cartilage destroys and bone erosion. Although the pathogenesis of RA is still unclear, the immune environment, particularly the lymphatic system, which is instrumental to immune cell surveillance and interstitial fluid balance, plays vital roles in the process of RA. Herein, an inflammation specific environment activated methotrexate-encapsulated nanomedicine (MTX@NPs) was constructed for RA treatment, which accumulated in inflamed joints, and released MTX in the specific RA microenvironment. Notably, MTX@NPs could regulate the immune environment including reducing the expressions of inflammatory cytokines of macrophages and the inflammatory level of lymphatic epithelial cells (LECs), and ameliorating the lymphatic vessel contraction and drainage. In vitro and In vivo studies illustrated that MTX@NPs exhibited a high RA therapeutic efficacy and insignificant systemic toxicity owing to the suppression of the inflammation response and the improved lymphatic functions of RA joints. It suggests that the nanomedicine paves a potential way to the clinical practice of autoimmune diseases treatments via the regulation of immune environment and lymphatic functions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据